By Memorandum Opinion entered by The Honorable Gregory M. Sleet in Pfizer Inc., et al. v. Mylan Pharmaceuticals Inc., C.A. No. 10-528-GMS (D.Del., October 22, 2014), the Court, following a four day bench trial and after having considered the entire record in the case and the applicable law, concluded that none of the asserted claims of the patents-in-suit, claims 5 and 21 of U.S. Patent Number 6,573,293 (“the ‘293 patent”) and claims 1 and 2 of U.S. Patent Number 7,125,905 (“the ‘905 patent”), are invalid due to obviousness.  Accordingly, the Court found in favor of Pfizer and against Mylan on the issue of obviousness.

A copy of the Memorandum Opinion is attached.